

## Supplementary Online Content


Simonett JM, Skalet AH, Lujan BJ, Neuwelt EA, Ambady P, Lin P. Risk factors and disease course for blood-brain barrier disruption–associated maculopathy. *JAMA Ophthalmol*. Published online December 3, 2020. doi:10.1001/jamaophthalmol.2020.5329

**eFigure 1.** Multimodal Retinal Imaging of Blood-Brain Barrier Disruption (BBBD) Associated Maculopathy

**eFigure 2.** Maculopathy Progression and Geographic Atrophy After Completion of Blood-Brain Barrier Disruption (BBBD) Therapy


**eFigure 3.** Maculopathy Evolution After Completion of Blood-Brain Barrier Disruption (BBBD) Therapy

**This supplementary material has been provided by the authors to give readers additional information about their work.**




**eFigure 1. Multimodal retinal imaging of blood-brain barrier disruption (BBBD) associated maculopathy.** Multimodal retinal imaging in 12 patients treated with blood-brain barrier disruption therapy and associated maculopathy grouped by morphologic features: 1<sup>st</sup> row – reticular pigmentary changes, 2<sup>nd</sup> row – parafoveal bull's eye or RPE stippling, 3<sup>rd</sup> row – geographic atrophy of the RPE.

**A** Time from end of BBBD therapy



**B** Time from end of BBBD therapy



**C** Time from end of BBBD therapy

